Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?
Sharon R. Sznitman, Barbara Broers, Reto Auer, Kali Tal
Int J Drug Policy July 26, 2024 DOI: 10.1016/j.drugpo.2024.104521 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelic medicine Psychedelic treatment Patient safety Patient well-being Patient protection Patient safeguards Patient care Risk mitigation Risk management Risk prevention Harm reduction Safety protocols Clinical safeguards Clinical guidelines Best practices Therapeutic protocols Treatment standards Clinical practice |
| Citations | 1 |
| Key points | Argues that psychedelic-assisted therapy poses particular risks to vulnerable patients and proposes guidelines to prevent or mitigate those harms. |
Abstract
Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?